Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The role of prostaglandin E2 (PGE2) in the modulation of cell growth is well established incolorectal cancer. The aim of this study was to elucidate the significance of 15-hydroxyprostaglandin dehydrogenase(15-PGDH) down-regulation on the prognosis of hepatocellular carcinoma (HCC) patients. Methods: The expression of 15-PGDH in HCC cell lines and resected HCC tissues was investigated, and the correlationbetween 15-PGDH expression and HCC cell-line proliferation and patient survival was explored. Results: The interleukin-1-β-induced suppression of 15-PGDH did not change the proliferation of PLC and Huh-7cells in the MTS [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The induction of 15-PGDH bytransfection in HepG2 cells without baseline 15-PGDH expression was suppressed at day 2 of proliferation comparedwith empty-vector transfection, but there was no difference at day 3. Among the 153 patients who received curativeHCC resection between 2003 and 2004 at our institution, 15-PGDH expression was observed in resected HCC tissues in56 (36.6%), but the 5-year survival rate did not differ from that of the remaining 97 non-15-PGDH-expressing patients(57.1% vs 59.8%; P=0.93). Among 50 patients who exhibited baseline 15-PGDH expression in adjacent nontumor livertissues, 28 (56%) exhibited a reduction in 15-PGDH expression score in HCC tissues, and there was a trend towardfewer long-term survivors compared with the remaining 22 with the same or increment in their 15-PGDH expressionscore in HCC tissues. Conclusions: The prognostic significance of 15-PGDH down-regulation in HCC was not established in this study. However, maintenance of 15-PGDH expression could be a potential therapeutic target for a subgroup of HCC patientswith baseline 15-PGDH expression in adjacent nontumor liver tissue.
Abstract
Background/Aims: The role of prostaglandin E2 (PGE2) in the modulation of cell growth is well established incolorectal cancer. The aim of this study was to elucidate the significance of 15-hydroxyprostaglandin dehydrogenase(15-PGDH) down-regulation on the prognosis of hepatocellular carcinoma (HCC) patients. Methods: The expression of 15-PGDH in HCC cell lines and resected HCC tissues was investigated, and the correlationbetween 15-PGDH expression and HCC cell-line proliferation and patient survival was explored. Results: The interleukin-1-β-induced suppression of 15-PGDH did not change the proliferation of PLC and Huh-7cells in the MTS [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The induction of 15-PGDH bytransfection in HepG2 cells without baseline 15-PGDH expression was suppressed at day 2 of proliferation comparedwith empty-vector transfection, but there was no difference at day 3. Among the 153 patients who received curativeHCC resection between 2003 and 2004 at our institution, 15-PGDH expression was observed in resected HCC tissues in56 (36.6%), but the 5-year survival rate did not differ from that of the remaining 97 non-15-PGDH-expressing patients(57.1% vs 59.8%; P=0.93). Among 50 patients who exhibited baseline 15-PGDH expression in adjacent nontumor livertissues, 28 (56%) exhibited a reduction in 15-PGDH expression score in HCC tissues, and there was a trend towardfewer long-term survivors compared with the remaining 22 with the same or increment in their 15-PGDH expressionscore in HCC tissues. Conclusions: The prognostic significance of 15-PGDH down-regulation in HCC was not established in this study. However, maintenance of 15-PGDH expression could be a potential therapeutic target for a subgroup of HCC patientswith baseline 15-PGDH expression in adjacent nontumor liver tissue.
참고문헌 (25)
- Llovet JM, "Molecular targeted therapies in hepatocellular carcinoma", Hepatology, 48, pp.1312~1327 (2008)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Gupta RA, "Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2", Nat Rev Cancer, 1, pp.11~21 (2001)
- Dixon DA., "Regulation of COX-2 expression in human cancers", Prog Exp Tumor Res, 37, pp.52~71 (2003)
- Koga H, "Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation", Hepatology, 29, pp.688~696 (1999)
- Shiota G, "Cyclooxygenase-2 expression in hepatocellular carcinoma", Hepatogastroenterology, 46, pp.407~412 (1999)
- Simmons DL, "Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition", Pharmacol Rev, 56, pp.387~437 (2004)
- Vane JR, "Cyclooxygenases 1 and 2", Annu Rev Pharmacol Toxicol, 38, pp.97~120 (1998)
- Tsujii M, "Cyclooxygenase regulates angiogenesis induced by colon cancer cells", Cell, 93, pp.705~716 (1998)
- Charpigny G, "Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period", Biol Reprod, 57, pp.1032~1040 (1997)
- Casado M, "Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy", FASEB J, 15, pp.2016~2018 (2001)
- Abiru S, "Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells", Hepatology, 35, pp.1117~1124 (2002)
- Diaz-Munoz MD, "Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages", Biochem J, 443, pp.451~461 (2012)
- Na HK, "15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy", Biochem Pharmacol, 82, pp.1352~1360 (2011)
- Tai HH, "Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs)", Prostaglandins Other Lipid Mediat, 96, pp.37~40 (2011)
- Backlund MG, "15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer", J Biol Chem, 280, pp.3217~3223 (2005)
- Tai HH, "15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer", Prostaglandins Other Lipid Mediat, 83, pp.203~208 (2007)
- Pham H, "Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors", Pancreas, 39, pp.332~339 (2010)
- Thiel A, "15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer", Clin Cancer Res, 15, pp.4572~4580 (2009)
- Castro-Sanchez L, "Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma", Int J Biochem Cell Biol, 45, pp.2501~2511 (2013)
- Song HJ, "15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer", Cancer Invest, 29, pp.257~265 (2011)
- Mann JR, "Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression", Cancer Res, 66, pp.6649~6656 (2006)
- Yang L, "Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer", Cancer Res, 67, pp.5587~5593 (2007)
- Bresalier RS, "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial", N Engl J Med, 352, pp.1092~1102 (2005)
- Wolfe MM, "Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs", N Engl J Med, 340, pp.1888~1899 (1999)